The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 185-191

  Christoforidis, John B ^a   Wang, Jillian ^b   Jiang, Angela ^b   Willard, James ^d   Pratt, Cedric ^b   Abdel Rasoul, Mahmoud ^c   Roy, Sashwati ^c   Powell, Heather ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Ohio State University   (United States)

Author keywords

Bevacizumab; Ranibizumab; Tensile strength; Wound healing

Indexed keywords

BEVACIZUMAB; PLACEBO; RANIBIZUMAB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; ENDOTHELIUM CELL; HISTOPATHOLOGY; NONHUMAN; PUNCH BIOPSY; QUANTITATIVE STUDY; RABBIT; SCORING SYSTEM; TENSILE STRENGTH; WOUND HEALING;

EID: 84873161175     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S40537     Document Type: Article

References (37)

1. Erinieri JP, Fong AJ, Kemeny NE, Brown KT, Getraidman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117(6):1296-1301.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistic 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4);e25-e146.
3. Rogers S, McIntosh RL, Cheung N, et al. For the International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319 e1
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;359(5):427-434.
5. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53(2):376-381.
6. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized Phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clinic Oncol. 2009;27(20):3385-3390.
7. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62(6):707-709.
8. Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009;20(5):624-627.
9. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006;93(12):1456-1463.
10. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173-180.
11. Christoforidis JB, Rickets R, Pratt C, et al. The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol. 2012;6:61-69.
12. Reid RR, Said HK, Mogford JE, Mustoe TA. The future of wound healing: pursuing surgical models in transgenic and knockout mice. J Am College of Surgeons. 2004;199(4):578-585.
13. Gottrup F, Agren MS, Karlsmark T. Models for use in wound healing research: a survey focusing on in vitro and in vivo adult soft tissue. Wound Repair Regen. 2000;8(2):83-96.
14. Beck LS, Chen TL, Mikalauski P, Ammann AJ. Recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) enhances healing and strength of granulation skin wounds. Growth Factors. 1990;3(4):267-275.
15. Gould LJ, Leong M, Sonstein J, Wilson S. Optimization and validation of an ischemic wound model. Wound Repair Regen. 2005;13(6):576-582.
16. Gupta A, Jain GK, Raghubir. A time course study for the development of an immunocompromised wound model, using hydrocortisone. J Pharm Toxicol Methods. 1999;41(4):183-187.
17. Matsuda H, Koyama H, Sato H, et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med. 1998;187(3):297-306.
18. Howdieshell TR, Riegner C, Gupta V, Callaway D, Sathyanarayana McNeil PL. Normoxic wound fluid contains high levels of vascular endothelial growth factor. Ann Surg. 1998;228:707-715.
19. Hunt T. Wound Healing and Wound Infection: theory and surgical practice. New York, NY: Appleton-Century-Crofts; 1980.
20. Brown LF, Van De Water L, Harvery VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol. 1988;130:455-465.
21. Breuing K, Eriksson E, Liv P, Miller DR. Healing of partial thickness porcine skin wounds in a liquid environment. J Surg Res. 1992;52:50-58.
22. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11(4):373-382.
23. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clinic Oncol. 2005;23:4853-4855.
24. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008;26(Suppl 15): 4105.
25. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res. 2001;96:173-182.
26. Rich RM, Rosenfeld PJ, Pulafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
27. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-1047.
28. Martin DF, Maguire MG, Ying GS, et al; for the CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
29. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647-656.
30. Gaudreault J, Webb W, Van Hoy M, et al. Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits. AAPS Pharm Sci. 1999; (Suppl 1):3207.
31. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-α in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
32. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthlamol. 2008;146:508-512.
33. Maurice DM, Mishima S. Pharmacology of the Eye. New York: Springer-Verlag; 1984.
34. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. Epub December 30, 2011.
35. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-1884.
36. Lin YS, Nguyen C, Medoza JL, et al. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;299:371-378.
37. Watkins RH, D'Angio CT, Ryan RM, Patel A, Maniscalco WM. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol Lung Cell Mol Physiol. 1999;276:858-867.